NO20041432L - Sammensetninger som innbefatter COX-2 inhibitorer og aspirin. - Google Patents

Sammensetninger som innbefatter COX-2 inhibitorer og aspirin.

Info

Publication number
NO20041432L
NO20041432L NO20041432A NO20041432A NO20041432L NO 20041432 L NO20041432 L NO 20041432L NO 20041432 A NO20041432 A NO 20041432A NO 20041432 A NO20041432 A NO 20041432A NO 20041432 L NO20041432 L NO 20041432L
Authority
NO
Norway
Prior art keywords
aspirin
inhibitors
compositions
include cox
cox
Prior art date
Application number
NO20041432A
Other languages
English (en)
Other versions
NO20041432D0 (no
Inventor
Alberto Gimona
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20041432D0 publication Critical patent/NO20041432D0/no
Publication of NO20041432L publication Critical patent/NO20041432L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/60Salicylic acid; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20041432A 2001-10-11 2004-04-05 Sammensetninger som innbefatter COX-2 inhibitorer og aspirin. NO20041432L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0124459.9A GB0124459D0 (en) 2001-10-11 2001-10-11 Organic compounds
PCT/EP2002/011380 WO2003033001A1 (en) 2001-10-11 2002-10-10 Combinations comprising cox-2 inhibitors and aspirin

Publications (2)

Publication Number Publication Date
NO20041432D0 NO20041432D0 (no) 2004-04-05
NO20041432L true NO20041432L (no) 2004-06-28

Family

ID=9923664

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20041432A NO20041432L (no) 2001-10-11 2004-04-05 Sammensetninger som innbefatter COX-2 inhibitorer og aspirin.

Country Status (19)

Country Link
US (2) US20040235802A1 (no)
EP (1) EP1435968A1 (no)
JP (1) JP2005505606A (no)
KR (1) KR20040044891A (no)
CN (1) CN1625405A (no)
AU (1) AU2006249254A1 (no)
BR (1) BR0213181A (no)
CA (1) CA2458981A1 (no)
CO (1) CO5570661A2 (no)
GB (1) GB0124459D0 (no)
HU (1) HUP0401854A2 (no)
IL (1) IL160620A0 (no)
MX (1) MXPA04003365A (no)
NO (1) NO20041432L (no)
NZ (1) NZ532158A (no)
PL (1) PL369005A1 (no)
RU (1) RU2004114560A (no)
WO (1) WO2003033001A1 (no)
ZA (1) ZA200401302B (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040122011A1 (en) * 1998-12-23 2004-06-24 Pharmacia Corporation Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy
US7338971B2 (en) * 2001-08-30 2008-03-04 El-Naggar Mawaheb M Treatment of inflammatory, cancer, and thrombosis disorders
EP1492511B3 (fr) 2002-04-09 2012-05-02 Flamel Technologies Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s)
CA2487414A1 (en) 2002-06-11 2003-12-18 Nitromed, Inc. Nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use
EP1711454A4 (en) * 2004-01-27 2007-04-04 Merck Frosst Company COMBINATION THERAPY FOR TREATING DISEASES OR CONDITIONS INDUCED BY CYCLOOXYGENASE-2 IN PATIENTS WITH RISK OF THROMBOTIC CARDIOVASCULAR EVENTS
EP1888045B1 (en) * 2005-05-24 2010-09-08 Flamel Technologies Oral pharmaceutical composition for treating a cox-2 mediated condition
EP1919288A4 (en) * 2005-07-18 2009-12-16 Horizon Therapeutics Inc FAMOTIDINE- AND IBUPROGEN-BASED MEDICAMENTS AND THEIR ADMINISTRATION
US20080021078A1 (en) * 2006-07-18 2008-01-24 Horizon Therapeutics, Inc. Methods and medicaments for administration of ibuprofen
US20080020040A1 (en) * 2006-07-18 2008-01-24 Horizon Therapeutics, Inc. Unit dose form for administration of ibuprofen
US8067451B2 (en) 2006-07-18 2011-11-29 Horizon Pharma Usa, Inc. Methods and medicaments for administration of ibuprofen
US8067033B2 (en) 2007-11-30 2011-11-29 Horizon Pharma Usa, Inc. Stable compositions of famotidine and ibuprofen
US20100297224A1 (en) * 2006-08-31 2010-11-25 Horizon Therapeutics, Inc. NSAID Dose Unit Formulations with H2-Receptor Antagonists and Methods of Use
US9757529B2 (en) * 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US11696894B2 (en) * 2013-12-17 2023-07-11 Celsprin Llc Sequential administration of partitioned absorption aspirin or active aspirin derivative and COX-2 inhibitor
CN104173359B (zh) * 2014-09-05 2017-05-03 罗国安 一种降低罗非考昔副作用的消炎镇痛复方药物及其应用
WO2018167447A1 (en) * 2017-03-14 2018-09-20 University Of Sheffield Low dose aspirin (1-50 mg) together with antiplatelets such as ticagrelor of anticoagulants
US10272107B2 (en) * 2017-09-05 2019-04-30 Kenneth O. Russell Method for treating inflammatory brain disorders and traumatic brain injury
US10586872B2 (en) * 2018-07-03 2020-03-10 International Business Machines Corporation Formation of wrap-around-contact to reduce contact resistivity

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4743596A (en) * 1987-06-16 1988-05-10 Lapin Alfred R Anti-arthritic preparation
CO4960662A1 (es) * 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
US6136804A (en) * 1998-03-13 2000-10-24 Merck & Co., Inc. Combination therapy for treating, preventing, or reducing the risks associated with acute coronary ischemic syndrome and related conditions
PL351069A1 (en) * 1999-12-08 2003-03-10 Pharmacia Corp Valdecoxib compositions
GB0002336D0 (en) * 2000-02-01 2000-03-22 Glaxo Group Ltd Medicaments
AU2001285334A1 (en) * 2000-08-29 2002-03-13 Peter Van Patten Combination for the treatment of migraine comprising a cyclooxygenase-2 inhibitor and acetylsalicylic acid

Also Published As

Publication number Publication date
KR20040044891A (ko) 2004-05-31
ZA200401302B (en) 2005-01-04
CN1625405A (zh) 2005-06-08
AU2006249254A1 (en) 2007-01-04
CO5570661A2 (es) 2005-10-31
HUP0401854A2 (hu) 2004-12-28
IL160620A0 (en) 2004-07-25
GB0124459D0 (en) 2001-12-05
CA2458981A1 (en) 2003-04-24
RU2004114560A (ru) 2005-05-20
NZ532158A (en) 2006-04-28
BR0213181A (pt) 2004-08-31
WO2003033001A1 (en) 2003-04-24
JP2005505606A (ja) 2005-02-24
US20080027032A1 (en) 2008-01-31
EP1435968A1 (en) 2004-07-14
US20040235802A1 (en) 2004-11-25
MXPA04003365A (es) 2004-07-23
NO20041432D0 (no) 2004-04-05
PL369005A1 (en) 2005-04-18

Similar Documents

Publication Publication Date Title
DE60234125D1 (de) E inhibitoren
DK1401806T3 (da) Benzoylsulfonamider og sulfonylbenzamidiner til anvendelse som antitumormidler
NO20053356L (no) Aminindazolderivater og anvendelse derav som kinaseinhibitorer.
NO20041432L (no) Sammensetninger som innbefatter COX-2 inhibitorer og aspirin.
CY2015028I1 (el) Ενας αναστολεας ν-ακυλοσφιγγοσινο γλυκοζυλοτρανσφερασης
PT1370553E (pt) Inibidores de rhoquinase
ATE286049T1 (de) Pyridazinonaldose reductase inhibitoren
NO20042084L (no) 6-hydroksyisoflavoner, derivater og legemidler som omfatter disse
ZA200309298B (en) Skin-permeable selective cyclooxygenase-2 inhibitor composition.
NO20042719L (no) Substituerte 2-amino-cykloalkankarboksamider og deres anvendelse som protease-inhibitorer
NO20040654L (no) Gassmikrosfaere-liposomkompositter.
NO20035328D0 (no) Nye forbindelser og preparater som katepsinhibitorer
FI20010163L (fi) Palvelinarkitehtuuri
EP1463521A4 (en) INHIBITOR OF GP41
BR0103827B1 (pt) cola - pds.
ES1050491Y (es) Chupete infantil.
BR8101236Y1 (pt) desensiladeira.
ES1049424Y (es) Calendario-agenda polivalente.
ITRE20010032V0 (it) Gioiello.
ITRM20010076V0 (it) Linea altachiara.
ES1048877Y (es) Tetilla para biberon.
FI20010055A7 (fi) Rotaattori
SE0100694D0 (sv) DHFR inhibitors
UA5250S (uk) Робочий стіл
ES1052628Y (es) Extintor instantaneo.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application